Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24790610 | 0.93 | EPHX1 (0.55) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| SCHEMBL28231320 | 0.88 | EPHX1 (0.45) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| SCHEMBL28231346 | 0.88 | EPHX1 (0.45) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL28060562 | 0.86 | EPHX1 (0.44) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL28827123 | 0.86 | EPHX1 (0.44) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| SCHEMBL18380886 | 0.84 | CA1 (0.45) | EPHX1EPHX2CA1CA2ACHE | |
| SCHEMBL2051051 | 0.84 | — | — | |
| SCHEMBL20377850 | 0.84 | CA1 (0.45) | EPHX1EPHX2CA1CA2ACHE | |
| SCHEMBL9008707 | 0.81 | EPHX1 (0.52) | EPHX1POLBGNAI3GNAO1GNAI1 | |
| SCHEMBL11438411 | 0.80 | PKM (0.53) | EPHX1EPHX2CA1CA2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190116-B1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| CN-107108653-B | Pyrazolothiazole compound and medicine | 日本新药株式会社 | 2019-04-09 | — | — | CN | disclosed |
| US-9999622-B2 | Pyrazolothiazole compound and medicine comprising same | NIPPON SHINYAKU CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-9937176-B2 | Pyrazolothiazole compound and medicine comprising same | NIPPON SHINYAKU CO., LTD. (JP) | 2018-04-10 | — | — | US | disclosed |
| US-20180092919-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO., LTD. (JP) | 2018-04-05 | — | — | US | disclosed |
| US-20170252341-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3190116-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-7919517-B2 | Indazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-20090082348-A1 | INDAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7470717-B2 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20070117856-A1 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| CN-1777590-A | Indazole derivatives | KYOWA HAKKO KOGYO KK (JP) | 2006-05-24 | — | — | CN | disclosed |
| EP-1652842-A1 | INDAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6506777-B1 | Method for modulation of CCR-3 or CCR-5 chemokine receptor activity in a mammal in need thereof to treat asthma, allergic rhinitis, dermatitis, conjunctivitis, atherosclerosis or rheumatoid arthritis, which comprises the administration of an | MERCK & CO., INC. | 2003-01-14 | — | — | US | disclosed |
| US-6500844-B1 | PIPERIDINYL-1-METHYLCYCLOPENTANES AND STEREOISOMERS, USED AS ANTIINFLAMMATORY AND PROPHYLACTIC AGENTS AGAINST ALLERGIC RHINITIS, DERMATITIS, VISION DEFECTS, ASTHMA, ATHRITIS AND FOR PREVENTION OR DELAY OF AQUIRED IMMUNE DIFICIENCY SYNDROME | MERCK & CO., INC. | 2002-12-31 | — | — | US | disclosed |
| US-6472410-B1 | N-cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. | 2002-10-29 | — | — | US | disclosed |
| WO-2000076512-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6136827-A | PIPERIDINE COMPOUNDS AS DRUGS | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | disclosed |
| EP-1003514-A1 | CYCLIC AMINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999004794-A1 | CYCLIC AMINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092919-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | JAK1, JAK2, JAK3 | EPHX1 2636/4885POLB 3124/4885GNAI3 461/4885 |
| US-20070117856-A1 | Indazole derivatives | IGF1R, NR0B2, ADRA2B | EPHX1 3746/4885POLB 3091/4885GNAI3 1308/4885 |
| US-20090082348-A1 | INDAZOLE DERIVATIVES | IGF1R, NR0B2, ADRA2B | EPHX1 3746/4885POLB 3091/4885GNAI3 1308/4885 |
| US-20170252341-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | JAK1, JAK2, JAK3 | EPHX1 2636/4885POLB 3124/4885GNAI3 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.